Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company that develops treatments for serious diseases in which protein growth factors have a key role. Its focus areas are neuromuscular disease, cardiometabolic disorders, and other conditions. Its lead candidate, apitegromab, is a selective inhibitor of myostatin activation that is being developed for spinal muscular atrophy (SMA). The company's platform targets the latent forms of growth factors.